Emerging roles for the GPI-anchored tumor suppressor OPCML in cancers

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• OPCML is a GPI-anchored protein in the IgLON family, acting as a tumor suppressor.
• OPCML is silenced in over 80% of ovarian cancers via LOH and epigenetic silencing, correlating with poor patient survival.
• OPCML inactivation is observed in various cancers, indicating a conserved tumor suppressor role.

Purpose of the Study:

• To elucidate the mechanism of action of OPCML as a tumor suppressor.
• To investigate OPCML's role in regulating receptor tyrosine kinases (RTKs).
• To explore OPCML's potential as an anti-cancer therapeutic target.

Main Methods:

• In vitro and in vivo studies to assess OPCML's effect on cancer hallmarks and tumorigenesis.
• Analysis of OPCML's interaction with specific RTKs (EphA2, FGFRs, HER2, HER4, AXL).
• Investigation of OPCML's synergy with PTPRG in RTK inactivation.
• Identification of inactivating point mutations and crystal structure elucidation of OPCML.

Main Results:

• OPCML inhibits cancer phenotypes in vitro and abrogates tumorigenesis in vivo.
• OPCML downregulates/inactivates RTKs including EphA2, FGFR1, FGFR3, HER2, HER4, and AXL.
• OPCML sensitizes ovarian and breast cancers to specific therapies (lapatinib, erlotinib, anti-AXL).
• OPCML acts synergistically with PTPRG to inactivate pro-metastatic RTKs like AXL.
• Identification of inactivating mutations and structural insights into OPCML.

Conclusions:

• OPCML exerts its tumor suppressor function by modulating RTK activity.
• OPCML holds potential as a therapeutic target for sensitizing cancers to existing treatments.
• Understanding OPCML's structure-function relationship is crucial for developing novel anti-cancer strategies.